Results 291 to 300 of about 306,104 (338)

Advances on Albumin‐Based Carriers for Anticancer Drug Delivery

Advanced NanoBiomed Research, EarlyView.
This study systematically classifies the drug delivery modes of albumin by examining the characteristics of its surface‐active groups and internal binding sites. It provides an in‐depth analysis of various drug delivery strategies and their corresponding targeting mechanisms.
Ruoli Zhou, Rongbin Zhong, Zhonghui Luo, Hua Wei, Cui‐Yun Yu   +4 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nanobody-Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive Immunotherapy.

Small, 2021
Cancer immunotherapy based on natural killer (NK) cells is demonstrated to be a promising strategy. However, NK cells are deficient in ligands that target specific tumors, resulting in limited antitumor efficacy.
Liang Gong, Yanchun Li, Kaisa Cui, Ying Chen, Haofei Hong, Jiuming Li, Dan Li, Yuan Yin, Zhimeng Wu, Zhaohui Huang   +9 more
semanticscholar   +1 more source

In Vivo Tracking of Cell Viability for Adoptive Natural Killer Cell-based Immunotherapy by Ratiometric NIR-II Fluorescence Imaging.

Angewandte Chemie, 2021
The therapeutic efficacy of natural killer (NK) cells-based immunotherapy is greatly related with the survival of transplanted NK cells. However, no effective strategy was reported to monitor NK cell viability in adoptive immunotherapy in vivo .
Naishun Liao, Lichao Su, Youshi Zheng, Bixing Zhao, Ming Wu, Da Zhang, Huanghao Yang, Xiaolong Liu, Jibin Song   +8 more
semanticscholar   +1 more source

Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking for Enhanced Adoptive Immunotherapy in Solid Tumors.

Angewandte Chemie, 2020
Despite the success of natural killer (NK)-based adoptive immunotherapy in hematological malignancies, targeting solid tumors still has only limited therapeutic efficacy.
Da Zhang, Youshi Zheng, Ziguo Lin, Xiaolong Liu, Juan Li, Huanghao Yang, W. Tan   +6 more
semanticscholar   +1 more source

DNA-Edited Ligand Positioning on Red Blood Cells to Enable Optimized T Cell Activation for Adoptive Immunotherapy.

Angewandte Chemie, 2020
Artificial antigen presenting cells (APCs) with surface-anchored T cell activating ligands hold great potential in adoptive immunotherapy. However, it remains challenging to precisely control the ligand positioning on those platforms via conventional ...
Zhuang Liu, Lele Sun, Fengyun Shen, Jun Xu, Xiao Han, C. Fan   +5 more
semanticscholar   +1 more source

Adoptive immunotherapy

Current Opinion in Oncology, 1997
Some of the most dramatic advances in the treatment of cancer have used the immune system in combination with conventional or transplantation chemotherapy. Adoptive immunotherapy has been used for relapses after allogeneic bone marrow transplantation, and it has been particularly effective for chronic myeloid leukemia.
K, Ballen, F M, Stewart
openaire   +2 more sources

Adoptive immunotherapy for cancer

Immunological Reviews, 2013
SummaryRecent clinical success has underscored the potential for immunotherapy based on the adoptive cell transfer (ACT) of engineered T lymphocytes to mediate dramatic, potent, and durable clinical responses. This success has led to the broader evaluation of engineered T‐lymphocyte‐based adoptive cell therapy to treat a broad range of malignancies. In
Marco Ruella, Michael Kalos
openaire   +2 more sources

Adoptive immunotherapy against sarcomas

Expert Opinion on Biological Therapy, 2014
Conventional treatments reached an unsatisfactory therapeutic plateau in the treatment of advanced unresectable bone and soft tissue sarcomas that remain an unsolved medical need. Several evidences support the concept that adoptive immunotherapy may effectively integrate within the complex and multidisciplinary treatment of sarcomas.In this work we ...
MESIANO, GIULIA, LEUCI, Valeria, GIRAUDO, LIDIA, Gammaitoni L, Carnevale Schianca F, Cangemi M, Rotolo R, CAPELLERO, Sonia, PIGNOCHINO, YMERA, Grignani G, AGLIETTA, Massimo, SANGIOLO, Dario   +11 more
openaire   +3 more sources

Regulation of adoptive immunotherapy.

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2016
Adoptive immunotherapy using chimeric antigen receptor (CAR)-modified T cells has provided a major breakthrough in the treatment of hematological malignancies. In Japan, it is expected that CD19 CAR-T cell therapy will be introduced earlier in clinical B cell malignancy settings and/or that a novel CAR-T cell therapy will be developed for non-B cell ...
Nobuhiro Nishio, Satoshi Suzuki, Yozo Nakazawa   +2 more
openaire   +3 more sources

Cellular therapy: Adoptive immunotherapy with expanded natural killer cells

Immunological Reviews, 2019
Adoptive immunotherapy with natural killer cells was pioneered 30 years ago in human clinical trials with the development of cytokine‐induced killer cells—unfractionated peripheral blood mononuclear cell (PBMC) populations activated overnight with IL‐2 ...
Dean Anthony Lee
semanticscholar   +1 more source